NCT01915602
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01915602 |
| Title | Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Bayer |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | TUR | NZL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT |
CKB BOOST